Aditxt Inc ADTX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-06-19 |
| Shares Out. | 997,980,000 |
| Website | aditxt.com/ ↗ |
| Phone | 13027449800 |
| Employees | 26 |
| Revenue | $12,159 |
| Gross Profit | $2,868 |
| Net Income | -$16.2M |
| Free Cash Flow | -$18.6M |
| Total Assets | $13.9M |
| Total Liabilities | $49.1M |
| Equity | -$35.2M |
About Aditxt Inc
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.
Aditxt Inc is a publicly traded company under the ticker symbol ADTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2024-07-01)